Sunday, May 11, 2025
  • Login
No Result
View All Result
ForexTV
  • News
    • Top Corporate News
    • Lifestyle
    • Technology
    • Financial Markets News
  • Small Business
    • Digital Marketing Blog
    • Small Business Best Practices
    • Small Business Strategy
      • Sales Strategies
      • Marketing Strategies
  • Business Finance
    • Small Business-Lending Trends
    • Debt Service Coverage Ratio (DSCR)
    • Business Credit
      • Business Credit Blog
      • Business Loans
      • Merchant Cash Advances
      • Business Line of Credit
      • What is Alternative Business Lending?
    • Resources
      • Debt Service Coverage Ratio (DSCR) Calculator
  • Currency Focus
    • Crypto Focus
      • Bitcoin (BTC)
      • Ethereum (ETH)
      • Tether
      • BNB
      • Cardano (Ada)
      • Ripple (XRP)
      • Solana (SOL)
      • Dogecoin (DOGE)
      • Polkadot (DOT)
      • Tron (TRX)
      • Shiba Inu (SHIB)
      • Litecoin (LTC)
    • EURO (EUR)
    • Japanese Yen (JPY)
    • Great British Pound (GBP)
    • Swiss Franc (CHF)
    • New Zealand Dollar (NZD)
    • Canadian Dollar (CAD)
    • Australian Dollar (AUD)
  • Resources
    • Economic Calendar
    • Trader Education
      • Candlestick Pattern Intro
    • Live Forex Rates/Charts
      • Live Rates
      • Live Charts
    • Forex Trader Tools
      • Pivot Point Calculator
      • Currency Converter
      • Global Statistic Resources
    • Trading Terms
      • Forex Glossary
      • Glossary of Retirement Industry Terms
    • CPI Tools
      • CPI Inflation Calculator
      • CPI Average Price Calculator
  • Marketing Services
    • Digital Marketing Services
    • Digital Marketing Consulting
    • Search Engine Optimization (SEO)
    • Online Content Marketing
    • Digital Marketing Blog
    • Inbound Marketing Services
    • Email Marketing
    • Digital Marketing Rates
  • News
    • Top Corporate News
    • Lifestyle
    • Technology
    • Financial Markets News
  • Small Business
    • Digital Marketing Blog
    • Small Business Best Practices
    • Small Business Strategy
      • Sales Strategies
      • Marketing Strategies
  • Business Finance
    • Small Business-Lending Trends
    • Debt Service Coverage Ratio (DSCR)
    • Business Credit
      • Business Credit Blog
      • Business Loans
      • Merchant Cash Advances
      • Business Line of Credit
      • What is Alternative Business Lending?
    • Resources
      • Debt Service Coverage Ratio (DSCR) Calculator
  • Currency Focus
    • Crypto Focus
      • Bitcoin (BTC)
      • Ethereum (ETH)
      • Tether
      • BNB
      • Cardano (Ada)
      • Ripple (XRP)
      • Solana (SOL)
      • Dogecoin (DOGE)
      • Polkadot (DOT)
      • Tron (TRX)
      • Shiba Inu (SHIB)
      • Litecoin (LTC)
    • EURO (EUR)
    • Japanese Yen (JPY)
    • Great British Pound (GBP)
    • Swiss Franc (CHF)
    • New Zealand Dollar (NZD)
    • Canadian Dollar (CAD)
    • Australian Dollar (AUD)
  • Resources
    • Economic Calendar
    • Trader Education
      • Candlestick Pattern Intro
    • Live Forex Rates/Charts
      • Live Rates
      • Live Charts
    • Forex Trader Tools
      • Pivot Point Calculator
      • Currency Converter
      • Global Statistic Resources
    • Trading Terms
      • Forex Glossary
      • Glossary of Retirement Industry Terms
    • CPI Tools
      • CPI Inflation Calculator
      • CPI Average Price Calculator
  • Marketing Services
    • Digital Marketing Services
    • Digital Marketing Consulting
    • Search Engine Optimization (SEO)
    • Online Content Marketing
    • Digital Marketing Blog
    • Inbound Marketing Services
    • Email Marketing
    • Digital Marketing Rates
No Result
View All Result
ForexTV
No Result
View All Result
ADVERTISEMENTS
club Felene

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

by GlobeNewswire
November 19, 2023
in Top News
Reading Time: 5 mins read

LA JOLLA, Calif., Nov. 19, 2023 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute, and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Patrick Wen, Director at the Center for Neuro-Oncology at Dana-Farber Cancer Institute, Professor of Neurology, Harvard Medical School, presented new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) held November 15 – 19, 2023 in Vancouver, Canada. The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.

The primary endpoints of this Phase 2 clinical trial were safety and tolerability of MN-166 (ibudilast) and temozolomide (TMZ) combination treatment and efficacy of the combination treatment defined as progression-free survival rate at 6 months using the RANO criteria. MN-166 (ibudilast) and TMZ combination treatment was safe and well-tolerated, and no unexpected adverse effects were reported.

The highlights of the presentation are as follows:

Phase II clinical trial and immunohistochemistry study

  • The trial enrolled a total of 62 patients, including 36 newly diagnosed GBM (new GBM) patients and 26 recurrent GBM patients
    • Study participants’ mean age at screening was 58.9 years old for new GBM and 59.6 years old for recurrent GBM
    • 39% of patients were female in both groups
    • 94% of new GBM patients and 100% of recurrent GBM patients were Caucasian
  • All of the subjects received TMZ and MN-166 (ibudilast) treatment
  • Progression-Free Survival at 6 months (PFS6) was 44% for new GBM and 31% for recurrent GBM
  • Immunohistochemistry evaluation was performed for the patients whose pre-treatment tumor tissue samples were available from resected tumors at the initial surgery or biopsy to evaluate MIF (macrophage migration inhibitory factor), pERK, Ki67, CD3, CD11b, and CD74
    • CD3 expression was a good predictor for tumor progression at five months in recurrent glioblastoma subjects treated with MN-166 (ibudilast) and TMZ as subjects with progression had higher CD3 tumor infiltration than subjects with no progression (p<0.05)

Preclinical GBM model studies

  • C57BL/6 mice were intracranially injected with SB28 tumor cells at 4 weeks of life and then treated with either isotype control, vehicle control, MN-166 (ibudilast), anti-PD1, anti-PDL1 or a combination therapy
    • Median survival was 17 days for the vehicle and 28 days for the anti-PD1 inhibitor treatment alone. The addition of MN-166 (ibudilast) to the anti-PD1 inhibitor treatment significantly extended survival to a median of 66 days (p<0.001) for the combination therapy.
    • Median survival was 18 days for the vehicle and 26 days for the anti-PD-L1 inhibitor treatment alone. The addition of MN-166 (ibudilast) to the anti-PD-L1 inhibitor treatment significantly extended survival to a median of 34 days (p<0.05) for the combination therapy.

Kazuko Matsuda, M.D., Ph.D., M.P.H., Chief Medical Officer of MediciNova, Inc., commented, “We are very pleased to report the positive safety and efficacy results from the first GBM clinical trial of MN-166. GBM’s rapid progression and resistance to therapy poses a serious challenge to the medical community. Evaluation of MN-166 (ibudilast) as an adjuvant therapy with TMZ in GBM patients was generally safe and well tolerated. For the PFS6 primary efficacy endpoint, recurrent GBM patients showed a higher PFS6 rate compared to most historical studies. Moreover, the preclinical studies presented at this meeting support our postulation that adding MN-166 (ibudilast) to existing therapies, e.g., TMZ, anti-PD1 or anti-PD-L1, improves survival more than the individual therapies alone. We are excited by the findings presented by our esteemed collaborators and look forward to completing the full data analysis from the GBM clinical trial. We are eager to evaluate MN-166 (ibudilast) in combination with anti-PD1 and anti-PD-L1 therapies in a future clinical trial. MediciNova is grateful to the patients and families for their invaluable participation in our trial.”

About MN-166 (ibudilast)

MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative cervical myelopathy); and is also in development for glioblastoma, Long COVID, CIPN (chemotherapy-induced peripheral neuropathy), and substance use disorder. In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS).   

About MediciNova

MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by, or otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “estimates,” “projects,” “can,” “could,” “may,” “will,” “would,” “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova’s operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova’s collaborations with third parties, the availability of funds to complete product development plans and MediciNova’s ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2022 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

INVESTOR CONTACT:

Geoff O’Brien
Vice President
MediciNova, Inc.
info@medicinova.com

 

  • Author
  • Recent Posts
GlobeNewswire
GlobeNewswire
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
GlobeNewswire
Latest posts by GlobeNewswire (see all)
  • Faruqi & Faruqi Reminds The Bancorp Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 16, 2025 – TBBK - May 11, 2025
  • Mitolyn Reviews 2025: Ingredients, Real User Results, Pros and Cons! Honest Review Inside! - May 10, 2025
  • Tunnel to Towers Foundation Applauds New Executive Order Supporting Homeless Veterans and Pledges Continued Partnership with President Trump - May 10, 2025
ADVERTISEMENTS
americas favorite vodka

Related Posts

Faruqi & Faruqi Reminds The Bancorp Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 16, 2025 – TBBK

by GlobeNewswire
May 11, 2025
0

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In The Bancorp...

Mitolyn Reviews 2025: Ingredients, Real User Results, Pros and Cons! Honest Review Inside!

by GlobeNewswire
May 10, 2025
0

LOS ANGELES, May 10, 2025 (GLOBE NEWSWIRE) -- If you're dealing with stubborn weight, low energy, or sluggish metabolism, Mitolyn...

Bitcoin price rockets past $103K — Is it headed for new highs?

by Bitcoin News Editor
May 10, 2025
0

Bitcoin rockets to $102K, the Senate blocks a crypto bill over Trump ties, Ripple settles with the SEC, and Mashinsky...

Tunnel to Towers Foundation Applauds New Executive Order Supporting Homeless Veterans and Pledges Continued Partnership with President Trump

by GlobeNewswire
May 10, 2025
0

Staten Island, NY, May 10, 2025 (GLOBE NEWSWIRE) -- Statement from Frank Siller, Chairman and CEO of the Tunnel to...

Bitcoin eyes ‘crazy’ $160K, Mashinsky gets 12 years prison: Hodler’s Digest, May 4 – 10

by Bitcoin News Editor
May 10, 2025
0

A crypto analyst says Bitcoin is on its way to $160,000 or a "crazy number," Alex Mashinsky gets 12 years...

Global Times: Xi’s reply letter to young volunteers in West China highlights their role in boosting education, fostering ethnic unity

by GlobeNewswire
May 10, 2025
0

Xi Jinping praises youth volunteers teaching in Xinjiang, highlighting their role in education, unity, and border development.Beijing, China, May 10,...

Next Post

AUD to USD Forecast: RBA’s Hawkish Tone and PBoC Influence

Please login to join discussion
ADVERTISEMENTS
ForexTV Digital Marketing

Latest Posts

  • Faruqi & Faruqi Reminds The Bancorp Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 16, 2025 – TBBK May 11, 2025
  • Mitolyn Reviews 2025: Ingredients, Real User Results, Pros and Cons! Honest Review Inside! May 10, 2025
  • Bitcoin price rockets past $103K — Is it headed for new highs? May 10, 2025
  • Tunnel to Towers Foundation Applauds New Executive Order Supporting Homeless Veterans and Pledges Continued Partnership with President Trump May 10, 2025
  • Bitcoin eyes ‘crazy’ $160K, Mashinsky gets 12 years prison: Hodler’s Digest, May 4 – 10 May 10, 2025
  • About Us
  • Advertise
  • Careers
  • Contact
Privacy Policy / Terms and Conditions

© 2024 ForexTV.com

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Cookie Policy
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT
No Result
View All Result
  • News
    • Top Corporate News
    • Lifestyle
    • Technology
    • Financial Markets News
  • Small Business
    • Digital Marketing Blog
    • Small Business Best Practices
    • Small Business Strategy
      • Sales Strategies
      • Marketing Strategies
  • Business Finance
    • Small Business-Lending Trends
    • Debt Service Coverage Ratio (DSCR)
    • Business Credit
      • Business Credit Blog
      • Business Loans
      • Merchant Cash Advances
      • Business Line of Credit
      • What is Alternative Business Lending?
    • Resources
      • Debt Service Coverage Ratio (DSCR) Calculator
  • Currency Focus
    • Crypto Focus
      • Bitcoin (BTC)
      • Ethereum (ETH)
      • Tether
      • BNB
      • Cardano (Ada)
      • Ripple (XRP)
      • Solana (SOL)
      • Dogecoin (DOGE)
      • Polkadot (DOT)
      • Tron (TRX)
      • Shiba Inu (SHIB)
      • Litecoin (LTC)
    • EURO (EUR)
    • Japanese Yen (JPY)
    • Great British Pound (GBP)
    • Swiss Franc (CHF)
    • New Zealand Dollar (NZD)
    • Canadian Dollar (CAD)
    • Australian Dollar (AUD)
  • Resources
    • Economic Calendar
    • Trader Education
      • Candlestick Pattern Intro
    • Live Forex Rates/Charts
      • Live Rates
      • Live Charts
    • Forex Trader Tools
      • Pivot Point Calculator
      • Currency Converter
      • Global Statistic Resources
    • Trading Terms
      • Forex Glossary
      • Glossary of Retirement Industry Terms
    • CPI Tools
      • CPI Inflation Calculator
      • CPI Average Price Calculator
  • Marketing Services
    • Digital Marketing Services
    • Digital Marketing Consulting
    • Search Engine Optimization (SEO)
    • Online Content Marketing
    • Digital Marketing Blog
    • Inbound Marketing Services
    • Email Marketing
    • Digital Marketing Rates

© 2024 ForexTV.com